Paula San‐José
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Paula San‐José has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Ana Garrido
Department of Medicine Universitat Autonoma of Barcelona. Hospital de la Santa Creu i Sant Pau (IR Sant Pau). Institut Josep Carreras Barcelona Spain
1 shared publicationAngel Molina
Biochemistry and Molecular Genetics Department Core Laboratory, Biomedical Diagnostic Centre, Hospital Clinic Barcelona Spain
1 shared publication- Anna Giné‐Vilalta
Department of Medicine Universitat Autonoma of Barcelona. Hospital de la Santa Creu i Sant Pau (IR Sant Pau). Institut Josep Carreras Barcelona Spain
1 shared publication - Anna Merino
Biochemistry and Molecular Genetics Department Core Laboratory, Biomedical Diagnostic Centre, Hospital Clinic Barcelona Spain
1 shared publication Clara Martínez
Department of Medicine Universitat Autonoma of Barcelona. Hospital de la Santa Creu i Sant Pau (IR Sant Pau). Institut Josep Carreras Barcelona Spain
1 shared publicationDubraska Ramírez
Department of Medicine Universitat Autonoma of Barcelona. Hospital de la Santa Creu i Sant Pau (IR Sant Pau). Institut Josep Carreras Barcelona Spain
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in European Journal of Haematology
Measurable Residual Disease in IDH ‐Mutated AML : Identifying a Clinically Relevant Threshold for IDH Mutation Monitoring
Background: Isocitrate dehydrogenase ( IDH ) mutations are recurrent in acute myeloid leukemia (AML) and represent promising targets for measurable residual disease (MRD) monitoring. However, clinically validated strategies for IDH ‐based MRD assessment remain lacking. Methods: We evaluated the analytical performance and clinical utility of droplet digital PCR (ddPCR) for IDH mutation monitoring in a single‐center cohort of patients with IDH ‐mutated AML treated with curative intent. Healthy controls were included to characterize low‐level background signals and identify a clinical threshold. Results: ddPCR showed robust analytical performance, with a limit of detection of 0.01% variant allele frequency (VAF) and strong concordance with NGS. Low‐level IDH mutation signals were frequently detected in healthy individuals and in patients in remission. We identified 0.2% VAF as a candidate threshold for clinically relevant IDH MRD. Using this cutoff, post‐treatment detectable IDH MRD was associated with a higher 2‐year cumulative incidence of relapse (63.6% vs. 20%; p = 0.019) and inferior overall survival (70.6% vs. 92.9%; p = 0.04). Among patients negative by multiparameter flow cytometry, ddPCR identified residual IDH‐ mutated clones in 56% of cases, who showed higher relapse rates than double‐negative patients (50% vs. 0%; p = 0.031). Conclusions: A 0.2% VAF threshold was associated with clinically distinct outcomes and may provide a useful framework for IDH ‐based MRD assessment in AML.
- 2 November 2026
- Published by Wiley in European Journal of Haematology
Open AccessMeasurable Residual Disease in IDH ‐Mutated AML : Identifying a Clinically Relevant Threshold for IDH Mutation Monitoring
Background: Isocitrate dehydrogenase ( IDH ) mutations are recurrent in acute myeloid leukemia (AML) and represent promising targets for measurable residual disease (MRD) monitoring. However, clinically validated strategies for IDH ‐based MRD assessment remain lacking. Methods: We evaluated the analytical performance and clinical utility of droplet digital PCR (ddPCR) for IDH mutation monitoring in a single‐center cohort of patients with IDH ‐mutated AML treated with curative intent. Healthy controls were included to characterize low‐level background signals and identify a clinical threshold. Results: ddPCR showed robust analytical performance, with a limit of detection of 0.01% variant allele frequency (VAF) and strong concordance with NGS. Low‐level IDH mutation signals were frequently detected in healthy individuals and in patients in remission. We identified 0.2% VAF as a candidate threshold for clinically relevant IDH MRD. Using this cutoff, post‐treatment detectable IDH MRD was associated with a higher 2‐year cumulative incidence of relapse (63.6% vs. 20%; p = 0.019) and inferior overall survival (70.6% vs. 92.9%; p = 0.04). Among patients negative by multiparameter flow cytometry, ddPCR identified residual IDH‐ mutated clones in 56% of cases, who showed higher relapse rates than double‐negative patients (50% vs. 0%; p = 0.031). Conclusions: A 0.2% VAF threshold was associated with clinically distinct outcomes and may provide a useful framework for IDH ‐based MRD assessment in AML.
- 20 May 2025
- Published by Wiley in International Journal of Laboratory Hematology
Diagnostic Value of Botryoid Nuclei as a Biomarker of Severe Hyperthermia and Systemic Inflammation in Heatstroke and Neuroleptic Malignant Syndrome: A Challenge of Climate Change
Introduction: With the increasing frequency of heat waves due to climate change, heat‐related illnesses are becoming more common. Heatstroke is a life‐threatening condition characterized by hyperthermia and multiple organ failure. A rare morphological feature, botryoid nuclei, has been identified in the peripheral blood of patients with hyperthermia, but its significance is not well understood. This study investigates the diagnostic value of botryoid neutrophils as a potential marker of severe hyperthermia and systemic inflammation in heatstroke and neuroleptic malignant syndrome.Methods: We performed a retrospective analysis of six patients with hyperthermia who were admitted to the Hospital Clínic of Barcelona and the Hospital de la Santa Creu i Sant Pau during the summers of 2023 and 2024. Peripheral blood smears were analyzed using CellaVision DM9600, MC‐80, and DI60 analyzers. Blood cell counts were obtained using Advia 2120i and Sysmex XN analyzers. Biochemical parameters were measured using Atellica Solutions and Alinity analyzers.Results: Among the six cases, five were diagnosed with heatstroke and one with neuroleptic malignant syndrome. All patients exhibited botryoid nuclei in leucocytes (8% to 29%), more frequently observed in neutrophils. Hematologic findings included leucocytosis, neutrophilia with left shift, and thrombocytopenia. Biochemical analysis revealed significant organ dysfunction, including elevated liver enzymes, renal failure, and increased inflammatory markers, such as procalcitonin and lactic acid.Conclusion: Botryoid‐nuclei leucocytes may serve as a diagnostic marker for hyperthermia‐related conditions, including heatstroke and neuroleptic malignant syndrome. This finding underscores the relevance of early recognition and intervention in patients presenting with hyperthermia and systemic inflammation.
- 20 May 2025
- Published by Wiley in International Journal of Laboratory Hematology
Diagnostic Value of Botryoid Nuclei as a Biomarker of Severe Hyperthermia and Systemic Inflammation in Heatstroke and Neuroleptic Malignant Syndrome: A Challenge of Climate Change
Introduction: With the increasing frequency of heat waves due to climate change, heat‐related illnesses are becoming more common. Heatstroke is a life‐threatening condition characterized by hyperthermia and multiple organ failure. A rare morphological feature, botryoid nuclei, has been identified in the peripheral blood of patients with hyperthermia, but its significance is not well understood. This study investigates the diagnostic value of botryoid neutrophils as a potential marker of severe hyperthermia and systemic inflammation in heatstroke and neuroleptic malignant syndrome.Methods: We performed a retrospective analysis of six patients with hyperthermia who were admitted to the Hospital Clínic of Barcelona and the Hospital de la Santa Creu i Sant Pau during the summers of 2023 and 2024. Peripheral blood smears were analyzed using CellaVision DM9600, MC‐80, and DI60 analyzers. Blood cell counts were obtained using Advia 2120i and Sysmex XN analyzers. Biochemical parameters were measured using Atellica Solutions and Alinity analyzers.Results: Among the six cases, five were diagnosed with heatstroke and one with neuroleptic malignant syndrome. All patients exhibited botryoid nuclei in leucocytes (8% to 29%), more frequently observed in neutrophils. Hematologic findings included leucocytosis, neutrophilia with left shift, and thrombocytopenia. Biochemical analysis revealed significant organ dysfunction, including elevated liver enzymes, renal failure, and increased inflammatory markers, such as procalcitonin and lactic acid.Conclusion: Botryoid‐nuclei leucocytes may serve as a diagnostic marker for hyperthermia‐related conditions, including heatstroke and neuroleptic malignant syndrome. This finding underscores the relevance of early recognition and intervention in patients presenting with hyperthermia and systemic inflammation.